Dr. Patrick Smith and Dr. Craig Rayner of d3 Medicine have been appointed drug development advisors to Arch Biopartners. In this capacity, Drs. Smith and Rayner will provide expertise in all aspects of drug development for new drug products emerging from the Arch portfolio, including preclinical planning, clinical trial design, cGMP manufacturing and government relations. Dr. Smith, the former head of U.S. clinical pharmacology for Roche, has more than 15 years of global drug development experi...